Logo image of CMPI

CHECKMATE PHARMACEUTICALS IN (CMPI) Stock Fundamental Analysis

USA - NASDAQ:CMPI - US1628181083 - Common Stock

10.5
+0.02 (+0.19%)
Last: 5/27/2022, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CMPI. CMPI was compared to 531 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CMPI as it has an excellent financial health rating, but there are worries on the profitability. CMPI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CMPI had negative earnings in the past year.
CMPI Yearly Net Income VS EBIT VS OCF VS FCFCMPI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 -20M -40M -60M

1.2 Ratios

Industry RankSector Rank
ROA -94.34%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CMPI Yearly ROA, ROE, ROICCMPI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 0 2K 4K

1.3 Margins

CMPI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMPI Yearly Profit, Operating, Gross MarginsCMPI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021

More info and screens

7

2. Health

2.1 Basic Checks

CMPI has about the same amout of shares outstanding than it did 1 year ago.
CMPI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CMPI Yearly Shares OutstandingCMPI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 5M 10M 15M 20M
CMPI Yearly Total Debt VS Total AssetsCMPI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

CMPI has an Altman-Z score of 4.87. This indicates that CMPI is financially healthy and has little risk of bankruptcy at the moment.
There is no outstanding debt for CMPI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.87
ROIC/WACCN/A
WACCN/A
CMPI Yearly LT Debt VS Equity VS FCFCMPI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 0 50M -50M 100M

2.3 Liquidity

CMPI has a Current Ratio of 5.20. This indicates that CMPI is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 5.20 indicates that CMPI has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 5.2
Quick Ratio 5.2
CMPI Yearly Current Assets VS Current LiabilitesCMPI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

CMPI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 69.23%, which is quite impressive.
EPS 1Y (TTM)69.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 5.24% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-8.64%
EPS Next 2Y8.68%
EPS Next 3Y-15.32%
EPS Next 5Y5.24%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CMPI Yearly Revenue VS EstimatesCMPI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 10M 20M 30M 40M 50M
CMPI Yearly EPS VS EstimatesCMPI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CMPI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CMPI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMPI Price Earnings VS Forward Price EarningsCMPI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -2.6
CMPI Per share dataCMPI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

CMPI's earnings are expected to decrease with -15.32% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.68%
EPS Next 3Y-15.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CMPI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHECKMATE PHARMACEUTICALS IN

NASDAQ:CMPI (5/27/2022, 8:00:01 PM)

10.5

+0.02 (+0.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2022-05-12/amc
Earnings (Next)08-10 2022-08-10
Inst Owners0.48%
Inst Owner Change0%
Ins Owners23.33%
Ins Owner Change0%
Market Cap231.40M
Revenue(TTM)N/A
Net Income(TTM)-63.15M
Analysts82.5
Price Target12.75 (21.43%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.21
P/tB N/A
EV/EBITDA -2.6
EPS(TTM)-2.92
EYN/A
EPS(NY)-2.33
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS2.5
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -94.34%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.2
Quick Ratio 5.2
Altman-Z 4.87
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.31%
EPS Next Y-8.64%
EPS Next 2Y8.68%
EPS Next 3Y-15.32%
EPS Next 5Y5.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

CHECKMATE PHARMACEUTICALS IN / CMPI FAQ

Can you provide the ChartMill fundamental rating for CHECKMATE PHARMACEUTICALS IN?

ChartMill assigns a fundamental rating of 3 / 10 to CMPI.


Can you provide the valuation status for CHECKMATE PHARMACEUTICALS IN?

ChartMill assigns a valuation rating of 1 / 10 to CHECKMATE PHARMACEUTICALS IN (CMPI). This can be considered as Overvalued.


What is the profitability of CMPI stock?

CHECKMATE PHARMACEUTICALS IN (CMPI) has a profitability rating of 1 / 10.


What is the financial health of CHECKMATE PHARMACEUTICALS IN (CMPI) stock?

The financial health rating of CHECKMATE PHARMACEUTICALS IN (CMPI) is 5 / 10.